-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TST-005 in Small-Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TST-005 in Small-Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.TST-005 in Small-Cell Lung Cancer Drug Details:TST-005 is under development for the...
-
Product Insights
Interstitial Cystitis (Painful Bladder Syndrome) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Interstitial Cystitis Clinical Trials Overview The report provides an overview of the Interstitial Cystitis (Painful Bladder Syndrome) clinical trial scenario and top-line data relating to the clinical trials. It also includes an overview of trial numbers and their average enrolment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type. Key Regions · North America · Asia-Pacific · Europe · ...
-
Product Insights
KYORIN Pharma Grp – Takaoka Pharmaceutical Production Plant – Toyama
Equip yourself with the essential tools needed to make informed and profitable decisions with our KYORIN Pharma Grp - Takaoka Pharmaceutical Production Plant - Toyama report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep...
-
Company Profile
KYORIN Holdings Inc – Company Profile
KYORIN Pharmaceutical Co Ltd (Kyorin), formerly KYORIN Holdings Inc, manufactures, develops and commercializes pharmaceuticals including new ethical drugs, generic drugs and over-the-counter (OTC) drugs. The company offers diagnostics, reagents, intermediates, industrial chemicals and other products. Kyorin markets its products under Kipres, Mucodyne, Pentasa, Uritos, Ketas, Flutiform, Milton, Rubysta and other brands. It also provides solutions to medical professionals in infection-related fields. The company operates its business through its subsidiaries KYORIN Rimedio Co Ltd and KYORIN Pharmaceutical Group Facilities Co Ltd...
Add to Basket -
Company Profile
MediciNova Inc – Company Profile
MediciNova Inc (MediciNova) is a biopharmaceutical company that focuses on acquiring, and developing novel, small-molecule therapeutics for the treatment of neurological, respiratory, and liver diseases. MediciNova’s developmental pipeline includes core programs for the treatment of fibrotic diseases; neurological disorders; and respiratory diseases. The company’s non-core programs formulations developed for indications include treatment of bronchial asthma; interstitial cystitis; solid tumors; and for the treatment of preterm labor. It has partnerships with various companies such as Angiogene Pharmaceuticals Ltd, Kyorin Pharmaceutical Co...
Add to Basket -
Product Insights
Acute Myelocytic Leukemia (AML) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
AML Pipeline Products Market Report Overview Acute myelocytic leukemia (AML), also known as acute myelogenous leukemia is a type of cancer that affects the blood and the bone marrow. Immature white blood cells accumulate in the bone marrow thus blocking the production of normal blood cells. These cells further enter the bloodstream and spread to the other parts of the body. Symptoms of AML include fatigue, fever, bleeding, breathing problems, and weight loss. The predisposing factors involved are exposed to...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – KPRA-218
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry KPRA-218 Drug Details KPRA-218 is under development for the treatment of rhinovirus infections. It...
-
Track & Monitor
Innovation in Pharmaceuticals: Genetically modified immunosuppresants
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the Pharmaceuticals industry’s Genetically modified immunosuppresants segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or altered based...
-
Product Insights
Multiple Sclerosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Multiple Sclerosis Pipeline Drugs Development Market Report Overview Multiple sclerosis (MS) is a potentially debilitating disease in which the body's immune system eats away at the protective sheath (myelin) that covers nerves. Damage to myelin causes interference in the communication between the brain, spinal cord, and other areas of the body. Symptoms include numbness or weakness in one or more limbs, double vision or blurring of vision, tingling or pain in parts of the body, fatigue, and slurred speech. The...